Current treatment options for metastatic castration‐resistant prostate cancer
MUDr. Aneta Rozsypalová1, doc. MUDr. Josef Dvořák, Ph.D.1, MUDr. Igor Richter, Ph.D.2, MUDr. David Buka3, MUDr. Jana Grimová4, MUDr. Michaela Matoušková1
1) Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
2) Oddělení klinické onkologie, Krajská nemocnice Liberec, a.s.
3) Klinika onkologie a radioterapie LF UK a FN Hradec Králové
4) Onkologická klinika 2. LF UK a FN v Motole, Praha
Prostate cancer is mostly hormonal dependent disease from the beginning but during sometime develops in castration-resistant prostate cancer - it is time when the progression of the disease is occurring despite androgen deprivation therapy and patients have a testosterone level drawn. Many trials are interested in finding new opportunities of treatment of this stage. Thanks these trials we have new drugs: in category of cytotoxic chemotherapy cabazitaxel, new generation of androgen deprivation therapy ARTA (abirateron acetate, enzalutamide). For patients with bone-only metastatic disease, without visceral metastasis, there is an opportunity to use radium 223. And we can't forget immunotherapy agents as sipuleucel-T and check point inhibitors. So we have many opportunities which significantly prolong median of overall survival with good quality of life.
metastatic castration-resistant prostate cancer, docetaxel, cabazitaxel, abiraterone, enzalutamide, radium 223
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...